FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890039919> ?p ?o ?g. }

• W2890039919 endingPage "3025" @default.
• W2890039919 startingPage "3025" @default.
• W2890039919 abstract "3025 Background: Axi-cel is an autologous anti-CD19 CAR T cell therapy. ZUMA-1 is a multicenter, registrational trial of axi-cel in patients (pts) with refractory/aggressive B-cell non-Hodgkin lymphoma (NHL). In a pre-specified interim analysis, ZUMA-1 met its primary endpoint with 76% objective response rate and 47% complete response (Blood 2016;128:LBA-6). We describe, for the first time, a tumor microenvironment immune gene signature associated with CAR T cell treatment (tx) of NHL pts. Methods: Paired biopsies, pre- and within 3 weeks post-axi-cel tx, were analyzed by digital gene expression followed by a pre-specified bioinformatics algorithm applied to IGES15 and IGES21 genes involved in immune-mediated tumor regression (Immunosign; Galon Immunity 2013). Immunosign profiles expression of a pre-defined set of effector T cell, Th1, chemokine, and cytokine genes. Expression analysis and hierarchical clustering were used to define an axi-cel-related tumor immune gene signature. Wilcoxon signed rank test with multiple test correction by FDR (Benjamini-Yekutieli) was used. Results: Gene expression profile comparisons of pre- and post-axi-cel tx biopsies from 14 pts showed profound changes in gene expression within the tumor environment after infusion. The most upregulated genes post-axi-cel tx were CCL5 (RANTES), CTLA4, and GZMA (log 2 fold change > 2, P< 0.05, FDR < 0.050). Immune checkpoints PD-L1 and LAG3 were also upregulated post-axi-cel (log 2 fold change > 1.6, P< 0.05, FDR < 0.055). Other genes associated with T cell proliferation, homing, and effector function were also upregulated: IL-15, GZMK, CXC3CL1 (Fractalkine), CD8A, and STAT4 (log 2 fold change > 1.6; P< 0.05, FDR < 0.074). Additional baseline tumor characteristics and associative analysis will be presented. Conclusions: We define a mechanistic tumor immune gene signature in NHL pts associated with axi-cel tx. This signature comprises upregulation of T cell activation, effector, chemokine, and immune checkpoint genes. These data will potentially lead to rational optimization of T cell interventions in cancer Clinical trial information: NCT02348216." @default.
• W2890039919 created "2018-09-27" @default.
• W2890039919 creator A5005446802 @default.
• W2890039919 creator A5005565037 @default.
• W2890039919 creator A5021218555 @default.
• W2890039919 creator A5021394406 @default.
• W2890039919 creator A5024200471 @default.
• W2890039919 creator A5037526878 @default.
• W2890039919 creator A5038112938 @default.
• W2890039919 creator A5040504519 @default.
• W2890039919 creator A5064185471 @default.
• W2890039919 creator A5064752432 @default.
• W2890039919 creator A5066129729 @default.
• W2890039919 creator A5069555659 @default.
• W2890039919 creator A5070180314 @default.
• W2890039919 creator A5070615133 @default.
• W2890039919 creator A5077959781 @default.
• W2890039919 creator A5078543360 @default.
• W2890039919 creator A5081926380 @default.
• W2890039919 creator A5082467973 @default.
• W2890039919 creator A5085418536 @default.
• W2890039919 creator A5090694142 @default.
• W2890039919 date "2017-05-20" @default.
• W2890039919 modified "2023-10-16" @default.
• W2890039919 title "Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)." @default.
• W2890039919 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.3025" @default.
• W2890039919 hasPublicationYear "2017" @default.
• W2890039919 type Work @default.
• W2890039919 sameAs 2890039919 @default.
• W2890039919 citedByCount "40" @default.
• W2890039919 countsByYear W28900399192017 @default.
• W2890039919 countsByYear W28900399192018 @default.
• W2890039919 countsByYear W28900399192019 @default.
• W2890039919 countsByYear W28900399192020 @default.
• W2890039919 countsByYear W28900399192021 @default.
• W2890039919 countsByYear W28900399192022 @default.
• W2890039919 countsByYear W28900399192023 @default.
• W2890039919 crossrefType "journal-article" @default.
• W2890039919 hasAuthorship W2890039919A5005446802 @default.
• W2890039919 hasAuthorship W2890039919A5005565037 @default.
• W2890039919 hasAuthorship W2890039919A5021218555 @default.
• W2890039919 hasAuthorship W2890039919A5021394406 @default.
• W2890039919 hasAuthorship W2890039919A5024200471 @default.
• W2890039919 hasAuthorship W2890039919A5037526878 @default.
• W2890039919 hasAuthorship W2890039919A5038112938 @default.
• W2890039919 hasAuthorship W2890039919A5040504519 @default.
• W2890039919 hasAuthorship W2890039919A5064185471 @default.
• W2890039919 hasAuthorship W2890039919A5064752432 @default.
• W2890039919 hasAuthorship W2890039919A5066129729 @default.
• W2890039919 hasAuthorship W2890039919A5069555659 @default.
• W2890039919 hasAuthorship W2890039919A5070180314 @default.
• W2890039919 hasAuthorship W2890039919A5070615133 @default.
• W2890039919 hasAuthorship W2890039919A5077959781 @default.
• W2890039919 hasAuthorship W2890039919A5078543360 @default.
• W2890039919 hasAuthorship W2890039919A5081926380 @default.
• W2890039919 hasAuthorship W2890039919A5082467973 @default.
• W2890039919 hasAuthorship W2890039919A5085418536 @default.
• W2890039919 hasAuthorship W2890039919A5090694142 @default.
• W2890039919 hasConcept C104317684 @default.
• W2890039919 hasConcept C116484652 @default.
• W2890039919 hasConcept C150194340 @default.
• W2890039919 hasConcept C203014093 @default.
• W2890039919 hasConcept C2776090121 @default.
• W2890039919 hasConcept C2776107976 @default.
• W2890039919 hasConcept C2778957590 @default.
• W2890039919 hasConcept C2779733811 @default.
• W2890039919 hasConcept C502942594 @default.
• W2890039919 hasConcept C55493867 @default.
• W2890039919 hasConcept C71924100 @default.
• W2890039919 hasConcept C79484868 @default.
• W2890039919 hasConcept C86803240 @default.
• W2890039919 hasConcept C8891405 @default.
• W2890039919 hasConceptScore W2890039919C104317684 @default.
• W2890039919 hasConceptScore W2890039919C116484652 @default.
• W2890039919 hasConceptScore W2890039919C150194340 @default.
• W2890039919 hasConceptScore W2890039919C203014093 @default.
• W2890039919 hasConceptScore W2890039919C2776090121 @default.
• W2890039919 hasConceptScore W2890039919C2776107976 @default.
• W2890039919 hasConceptScore W2890039919C2778957590 @default.
• W2890039919 hasConceptScore W2890039919C2779733811 @default.
• W2890039919 hasConceptScore W2890039919C502942594 @default.
• W2890039919 hasConceptScore W2890039919C55493867 @default.
• W2890039919 hasConceptScore W2890039919C71924100 @default.
• W2890039919 hasConceptScore W2890039919C79484868 @default.
• W2890039919 hasConceptScore W2890039919C86803240 @default.
• W2890039919 hasConceptScore W2890039919C8891405 @default.
• W2890039919 hasIssue "15_suppl" @default.
• W2890039919 hasLocation W28900399191 @default.
• W2890039919 hasOpenAccess W2890039919 @default.
• W2890039919 hasPrimaryLocation W28900399191 @default.
• W2890039919 hasRelatedWork W2136935687 @default.
• W2890039919 hasRelatedWork W3029948752 @default.
• W2890039919 hasRelatedWork W3030649553 @default.
• W2890039919 hasRelatedWork W3213906620 @default.
• W2890039919 hasRelatedWork W3214265212 @default.
• W2890039919 hasRelatedWork W4224234798 @default.
• W2890039919 hasRelatedWork W4308377693 @default.
• W2890039919 hasRelatedWork W4321368025 @default.

• next